Phase I, Open-Label Study of the Safety and Dosimetry of a 3-Dose Regimen of Escalating Doses of 177Lu-LNC1003 Injection in Adult Patients With Prostate Specific Membrane Antigen (PSMA)-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Latest Information Update: 29 Jul 2024
At a glance
- Drugs 177Lu LNC1003 (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- Sponsors Yantai LNC Biotechnology
Most Recent Events
- 24 Jul 2024 Planned initiation date changed from 7 May 2024 to 7 May 2025.
- 27 Mar 2024 Planned initiation date changed from 7 Mar 2024 to 7 May 2024.
- 08 Feb 2024 New trial record